
Vabysmo funding potential causes submission flurry
A Pharmac proposal to fund four new medicines from Roche, including the anti-VEGF treatment Vabysmo (faricimab) for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO), resulted in several hastily despatched submissions from the eyecare industry.











